Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 10 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% IN PLASTIC CONTAINER vs TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis and maintenance of nitrogen balance. The amino acids serve as substrates for protein synthesis, and their metabolism yields nitrogen for ureagenesis and carbon skeletons for gluconeogenesis or oxidation.
Travasol 2.75% in Dextrose 10% provides essential amino acids and caloric support via dextrose. Amino acids serve as substrates for protein synthesis and nitrogen balance, while dextrose provides glucose for energy metabolism. The combination is used for parenteral nutrition to maintain or restore positive nitrogen balance in patients unable to tolerate enteral nutrition.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour (equivalent to 0.035-0.07 g amino acids/kg/hour) for protein supplementation, not to exceed 0.2 g nitrogen/kg/day. Dosage individualized based on metabolic needs and clinical response.
Intravenous infusion. 1000 mL to 3000 mL per day, typically infused at 1.2-1.5 g amino acids/kg/day; adjust based on metabolic needs and fluid status.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is not typically defined as a single value because they are rapidly cleared from plasma for protein synthesis and metabolic processes. For labeled amino acids, the plasma clearance half-life ranges from 10-30 minutes. Clinically, the half-life is short; continuous infusion is required to maintain plasma amino acid levels. In patients with hepatic or renal dysfunction, half-life may be prolonged.
Not applicable as a single entity. Components are endogenous substances. Dextrose has a half-life of minutes due to rapid insulin-mediated uptake. Amino acids have variable half-lives (minutes to hours) depending on individual amino acid and metabolic state.
Aminosyn II 3.5% is a crystalline amino acid solution. The amino acids are metabolized and utilized for protein synthesis. Excess nitrogen is converted to urea in the liver and excreted renally as urea. Approximately 80-90% of infused amino acids are incorporated into proteins or metabolized; the remainder is excreted in urine as urea and other nitrogenous wastes. Fecal excretion is negligible (less than 2%) as amino acids are not significantly eliminated in bile. In patients with renal impairment, urea excretion is decreased, leading to azotemia.
TRAVASOL 2.75% IN DEXTROSE 10% is a combination of amino acids and dextrose. The amino acids are primarily metabolized and the nitrogen is excreted as urea in urine (renal, >90%). Dextrose is metabolized to CO2 and water; negligible biliary/fecal excretion.
Category C
Category C
Amino Acid Solution
Amino Acid Solution